NICE Guidance Recommends Treatment for Severe Hand Eczema
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




NICE Guidance Recommends Treatment for Severe Hand Eczema

LONDON -- August 26, 2009 -- The National Institute for Health and Clinical Excellence (NICE) has today published final guidance recommending the use of alitretinoin as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.

In these cases, alitretinoin is recommended, within its licensed indication, if the person is assessed as having severe disease.

Treatment should stop as soon as an adequate response (hands clear or almost clear) has been achieved. If the eczema is still defined by assessment as severe at 12 weeks, or if an adequate response hasn't been achieved by 24 weeks, then treatment should also be stopped.

"Eczema can have a huge impact on an individual, with the condition causing significant discomfort and in severe cases it can be painful," said Peter Littlejohns, NICE, London, United Kingdom.

"Scaling, blisters, redness and cracks in the skin are all common symptoms. Severe chronic hand eczema can affect a person's ability to use their hands, as well as potentially impacting on work and social aspects of their lives."

"This new guidance recommending alitretinoin will offer hope to adults whose severe chronic hand eczema hasn't been helped by strong topical corticosteroids," he said.

The guidance also recommends that only dermatologists, or physicians with experience in both managing severe chronic hand eczema and the use of systemic retinoids, should start and monitor treatment with alitretinoin.

Healthcare professionals should take into account any physical, sensory or learning disabilities, or other communication difficulties that could affect assessment responses.

SOURCE: National Institute for Health and Clinical Excellence


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities